Annovis Bio's Current Intellectual Property Portfolio Covers
the Use of Buntanetap, the Company's Lead Compound, to Treat
Neurodegenerative Diseases
With this Recent Filing, the Company Seeks Protection for
Buntanetap to Treat Infection-Dependent Neurological
Injuries
BERWYN,
Pa., June 9, 2022 /PRNewswire/ -- Annovis Bio
(NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug
platform company addressing neurodegenerative diseases, announced
today that the company submitted an international patent
application under the Patent Cooperation Treaty for its drug
platform buntanetap. The patent claims a method of inhibiting,
preventing, or treating neurological injuries due to viral,
bacterial, fungal, protozoan, or parasitic infections in
humans.
If granted, the patent application will add to the intellectual
property of the Company whose issued patents to date cover a wide
range of neurodegenerative diseases, including Alzheimer's disease
(AD), alpha-synucleopathies, such as Parkinson's disease (PD),
tauopathies, such as frontotemporal dementia (FTD) and chronic
traumatic encephalopathy (CTE) and acute injuries such as
stroke and traumatic brain injury. Neurotoxic protein levels, such
as APP/Abeta, alpha-synuclein and tau/phospho-tau, are high in
both chronic and acute brain injuries. Because infections, whether
viral, bacterial, or fungal, also cause an increase in these
neurotoxic proteins, buntanetap has the potential to protect the
brain from damage caused by infections. Data included in the filed
patent demonstrates that buntanetap lowers the levels of these
neurotoxic proteins protects astroglia from gingipains and restores
normal morphology and function to nerve cells. If granted, the
patent could provide intellectual property protection through
2042.
"This new patent application is not only another step in
strengthening the Company's position and expanding its intellectual
property portfolio but is also additional proof that consolidates
our platform. Simply put, the Annovis story and potential are much
broader than AD and PD. Because of its unique mode of action, our
drug has the potential to act on a variety of neurodegenerative
disorders," said Maria L. Maccecchini, Ph.D., Founder, President,
and CEO of Annovis.
"All indications for which we are testing buntanetap have a
shared basic mechanism: certain proteins are overexpressed, become
neurotoxic and trigger a cascade that slows axonal transport,
increases inflammation, reduces the viability and function of
neurons, and ultimately causes loss of function. Our drug reverses
this toxic cascade by selectively inhibiting the translation of
these neurotoxic proteins that are at play in these debilitating
diseases and, therefore, restores the affected function," Dr.
Maccecchini added.
Currently, Annovis is advancing buntanetap for the treatment of
AD and PD and expects to start recruitment for a Phase 3 clinical
trial in early PD patients this summer.
About Buntanetap
Buntanetap (previously known as ANVS401 or Posiphen) is an oral
translational inhibitor of neurotoxic aggregating proteins
(TINAPs), which mode of action leads to a lower level of neurotoxic
proteins and consequently less toxicity in the brain. In a Phase 2a
clinical trial in AD and PD patients, buntanetap was shown to be
well-tolerated and safe, and its pharmacokinetics were found to be
in line with levels measured earlier in humans, meeting both the
primary and secondary endpoints. Additionally, exploratory
endpoints were also met, as treatment with buntanetap resulted in
statistically significant improvement in motor function in PD
patients and cognition in AD patients.
About Annovis Bio, Inc.
Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug
platform company developing transformative therapies that treat
neurodegenerative disorders such as Alzheimer's disease (AD),
Parkinson's disease (PD) and other chronic and acute
neurodegenerative diseases. The Company believes that it is the
only company developing a drug that inhibits more than one
neurotoxic protein, improves the information highway of the nerve
cell, known as axonal transport, reduces inflammation and protects
nerve cells from dying in chronic and acute neurodegeneration.
Annovis conducted two Phase 2 studies: one in AD patients and one
in both AD and PD patients. In the AD/PD study, buntanetap showed
improvements in cognition and memory in AD as well as body and
brain function in PD patients.
For more information on Annovis Bio, please visit the Company's
website www.annovisbio.com and follow us on LinkedIn and
Twitter.
Forward-Looking
Statements
Statements in this press release contain "forward-looking
statements" that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as "anticipate,"
"expect," "believe," "will," "may," "should," "estimate,"
"project," "outlook," "forecast" or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness, and anticipated results of buntanetap clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.'s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2021, filed
with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Annovis Bio, Inc. undertakes no duty to update such information
except as required under applicable law.
Media and Investor Contact:
Nic Johnson
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/annovis-bio-submits-an-international-patent-application-to-cover-the-treatment-of-neurological-injuries-caused-by-infections-301564750.html
SOURCE Annovis Bio